Table 2.
Pharmacokinetics of quinine following a single oral dose (600 mg) of quinine sulphate to 10 healthy subjects during two treatment phases: control (quinine alone) and TAO (quinine +TAO). Data are presented as mean ±s.d. (95% CI).
| Measure | Control phase | TAO phase |
|---|---|---|
| AUC(0,∞) (mg l−1 h) | 63 ± 10 (57–69) | 118 ± 27* (102–135) |
| Cmax (mg l−1) | 3.2 ± 0.5 (2.9–3.4) | 3.8 ± 0.6**(3.5–4.2)) |
| tmax (h) | 3.3 ± 1.8 (2.2–4.4) | 3.6 ± 2.4 (2.1–5.1) |
| CL/F (l h−1) | 9.8 ± 1.8 (8.7–10.9) | 5.3 ± 1.0* (4.6–5.9) |
| t½ (h) | 12.3 ± 1.7 (11.2–13.3) | 20.0 ± 4.5* (17.2–22.8) |
| fe,Q (0,48 h) | 10.1 ± 2.4 (8.6–11.6) | 19.6 ± 5.5* (16.2–23.1) |
| CLR (l h−1) | 0.97 ± 0.21 (0.84–1.10) | 1.03 ± 0.35 (0.82–1.25) |
AUC(0,∞), area under the plasma concentration-time curve from zero to infinite time; Cmax, peak concentration; tmax, time to reach Cmax; CL/F, apparent oral clearance; t½, terminal elimination half-life; fe,Q, percent of the dose excreted unchanged in the urine; CLlR, renal clearance.
*
P < 0.001;
**
P < 0.01 (paired Student's t-test).